Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

Current oncology

J. Laskin¹  N. Daaboul²  V. Hirsh³  R. Juergens⁴  N. Leighl⁵  J. Rothenstein⁶  P. Cheung⁷  S. A. Laurie⁸  S. Brule⁹  D. J. Stewart^1,10  D. Hao^1,11  M. S. Tsao^1,12  S. Banerji^1,13  D. Roberge^1,14  G. Nicholas^1,15  R. MacRae^1,16  P. K. Cheema^1,17  N. Blais^1,18 

[1] BC Cancer Agency;Hôpital Charles-LeMoyne, Université de Sherbrooke;McGill, MUHC;McMaster University, Juravinski Cancer Centre;Princess Margaret Cancer Centre, University of Toronto;R.S. McLaughlin Durham Regional Cancer Center, Queen’s University;Sunnybrook Odette Cancer Centre, University of Toronto;The Ottawa Hospital Cancer Centre, University of Ottawa;The Ottawa Hospital and The University of Ottawa;The Ottawa Hospital, Ottawa Hospital Research Institute, University of Ottawa;Tom Baker Cancer Centre, University of Calgary;University Health Network-Princess Margaret Cancer Centre, University of Toronto;University of Manitoba;University of Montreal;University of Ottawa;University of Ottawa, The Ottawa Hospital;University of Toronto,William Osler Health System;Université de Montréal

关键词: Non-small-cell lung cancer;    advanced;    nsclc;    advanced;    oligometastatic disease;    oligoprogression;    pseudoprogression;   

DOI  :  10.3747/co.26.4116

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

BackgroundLittle evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment. MethodsAn expert panel was convened to define the clinical questions. Using case-based presentations, consensus practice recommendations for each clinical scenario were generated through focused, evidencebased discussions. ResultsTreatment strategies and best-practice or consensus recommendations are presented, with areas of consensus and areas of uncertainty identified. ConclusionsIn each situation, treatment has to be tailored to suit the individual patient, but with the intent of extending and maximizing the use of each line of treatment, while keeping treatment options in reserve for later lines of therapy. Patient participation in clinical trials examining these issues should be encouraged.

【 授权许可】

Unknown